Clinical and therapeutic predictors of disease outcomes in AQP4-IgG neuromyelitis optica spectrum disorder

A Kunchok; C Malpas; P Nytrova; EK Havrdova; R Alroughani; M Terzi; B Yamout; JY Hor; R Karabudak; C Boz; S Ozakbas; J Olascoaga; M Simo; F Granella; F Patti; P McCombe; T Csepany; B Singhal; R Bergamaschi; Y Fragoso; T Al-Harbi; R Turkoglu; J Lechner-Scott; G Laureys; C Oreja-Guevara; E Pucci; P Sola; D Ferraro; A Altintas; A Soysal; S Vucic; F Grand'Maison; G Izquierdo; S Eichau; A Lugaresi; M Onofrj; M Trojano; M Marriott; H Butzkueven; I Kister; T Kalincik

Journal article

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG neuromyelitis optica spectrum disorder

A Kunchok, C Malpas, P Nytrova, EK Havrdova, R Alroughani, M Terzi, B Yamout, JY Hor, R Karabudak, C Boz, S Ozakbas, J Olascoaga, M Simo, F Granella, F Patti, P McCombe, T Csepany, B Singhal, R Bergamaschi, Y Fragoso Show all

Multiple Sclerosis and Related Disorders | ELSEVIER SCI LTD | Published : 2020

DOI: 10.1016/j.msard.2019.101868

Abstract

Background: Aquaporin-4-IgG positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG+NMOSD are typically measured by relapse rate and disability. Using the MSBase, a multi-centre international registry, we aimed to examine the impact immunosuppressive therapies and patient characteristics as predictors of disease outcome measures in AQP4-IgG+NMOSD. Method: This MSBase cohort study of AQP4-IgG+NMOSD patients examined modifiers of relapse in a multivariable proportional hazards model and expanded disability status score (EDSS) using a mixed effects model. Results: 206 AQP4-IgG+ patients were incl..

View full abstract

University of Melbourne Researchers

Charles Malpas Author

Tomas Kalincik Author

Related Projects (3)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by GlaxoSmithKline

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council of Australia [project grants 1083539 and 1129189, and fellowships 1140766 and 1080518]. The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Bayer-Schering, Sanofi-Genzyme and Teva. The study was conducted separately and apart from the guidance of the sponsors.